US Patent 7,566,729: Pirfenidone Liver-Titration Claims, Patent Scope and Generic Entry Risk
US Patent 7,566,729 covers a narrow method of restarting and escalating pirfenidone in an idiopathic pulmonary fibrosis patient who developed a Grade 2 liver-function abnormality. The claims do not cover pirfenidone itself, all IPF treatment, or the standard 2,403 mg/day regimen in patients without the specified liver abnormality.
The central protected sequence is:
- A patient with IPF develops a Grade 2 liver-function abnormality after pirfenidone exposure.
- Pirfenidone is stopped or administered below 2,400 mg/day.
- Treatment is escalated to 2,400 mg/day or 2,403 mg/day.
- The regimen can include laboratory monitoring, administration three times daily with food, and specified dose-reduction steps.
The patent issued July 28, 2009, to InterMune, Inc. Its ordinary 20-year patent term ran in February 2025 based on the priority chain reflected in the patent record. The patent therefore is not an effective current barrier to ordinary U.S. generic pirfenidone entry, although historical Paragraph IV litigation and any related patents remain relevant to launch analysis. [1]
What does US Patent 7,566,729 protect?
The patent protects a post-adverse-event treatment protocol rather than a chemical compound or broad therapeutic indication.
| Claim |
Protected subject matter |
Scope |
| 1 |
Core treatment method |
IPF patient with a Grade 2 liver-function abnormality receives pirfenidone below 2,400 mg/day, followed by 2,400 or 2,403 mg/day |
| 2 |
Treatment interruption |
Pirfenidone is discontinued until liver biomarkers normalize |
| 3 |
First reduced-dose step |
Approximately 1,600 or 1,602 mg/day for about one week or until normalization |
| 4 |
Two-step escalation |
Approximately 800 or 801 mg/day, followed by approximately 1,600 or 1,602 mg/day |
| 5 |
Three-step rechallenge |
Discontinuation, followed by approximately 800 or 801 mg/day, then approximately 1,600 or 1,602 mg/day |
| 6 |
Administration conditions |
Three times daily with food |
| 7 |
Biomarker identity |
ALT, AST, bilirubin or alkaline phosphatase |
| 8 |
Monitoring |
Measurement of liver biomarkers during dose-reduction treatment |
| 9 |
Combined biomarkers |
ALT and AST |
The claim language uses “comprising,” which generally leaves room for additional treatment steps, monitoring, or supportive care. It does not, however, eliminate the requirement that the accused regimen contain the claimed sequence and patient history.
How should the claims be construed?
Claim 1 is the commercially important claim
Claim 1 requires each of the following elements:
- the disease is idiopathic pulmonary fibrosis;
- the patient previously received pirfenidone;
- the patient exhibited a Grade 2 abnormality in at least one liver-function biomarker after pirfenidone administration;
- pirfenidone was then administered below 2,400 mg/day for a period;
- treatment was followed by administration at 2,400 mg/day or 2,403 mg/day.
The claim is narrower than a claim to dose titration generally. A patient who starts pirfenidone at 267 mg three times daily and escalates to 801 mg three times daily without first developing a Grade 2 liver abnormality would not meet the principal patient-history limitation.
The alternative doses reflect the tablet-based dosing architecture:
| Daily dose |
Three-times-daily equivalent |
| 801 mg/day |
267 mg per administration |
| 1,602 mg/day |
534 mg per administration |
| 2,403 mg/day |
801 mg per administration |
| 2,400 mg/day |
Approximately 800 mg per administration |
The 2,403 mg/day regimen corresponds to the FDA-approved Esbriet maintenance dose of 801 mg three times daily. [2]
“Grade 2 abnormality” creates a material claim-construction issue
The claims do not define the numerical laboratory thresholds for Grade 2. The relevant standard may depend on the grading system used in the clinical or regulatory record, including the Common Terminology Criteria for Adverse Events in effect at the relevant time.
This limitation creates two opposing risks:
- A patent owner may argue that the patient’s documented laboratory event satisfies Grade 2 even if the prescribing record does not use that phrase.
- A generic manufacturer may argue that an unspecified liver-enzyme elevation does not establish the claimed Grade 2 condition.
The absence of a fixed numerical threshold increases the importance of the patient chart, prescribing instructions, adverse-event coding, and contemporaneous laboratory values.
Dependent claims narrow the protocol
Claims 2 through 5 require increasingly specific rechallenge sequences. Claim 5 is the most detailed:
- Stop pirfenidone for approximately one week or until liver biomarkers normalize.
- Administer approximately 800 or 801 mg/day for approximately one week.
- Administer approximately 1,600 or 1,602 mg/day for approximately one week.
- Return to 2,400 or 2,403 mg/day.
A protocol that skips the interruption step, uses a different duration, or moves directly from discontinuation to the full dose may fall outside the literal scope of these dependent claims while remaining potentially relevant to claim 1.
What FDA-approved dosing overlaps with the patent?
The FDA-approved Esbriet label recommends titration to 801 mg three times daily, or 2,403 mg/day, with food. The label also contains dose-modification instructions for liver-enzyme elevations and recommends liver-function testing before treatment and during therapy. [2]
| FDA labeling element |
Relationship to US 7,566,729 |
| 267 mg three times daily during initial titration |
Consistent with the patent’s low-dose architecture but does not alone satisfy claim 1 |
| 534 mg three times daily |
Corresponds to 1,602 mg/day in claims 3 to 5 |
| 801 mg three times daily |
Corresponds to 2,403 mg/day in claim 1 |
| Administration with food |
Recited in claim 6 |
| ALT and AST monitoring |
Recited in claims 7 to 9 |
| Dose interruption or reduction after liver abnormalities |
Overlaps the claimed clinical context |
The overlap between the FDA label and the patent is commercially significant because a generic label that includes the same liver-management instructions can create inducement or contributory-infringement arguments. That risk depends on the final label, prescribing instructions, knowledge of the patent, and whether the patent remains enforceable.
What patents protect pirfenidone and Esbriet?
The pirfenidone estate has included multiple categories of rights:
| Patent category |
Representative protection |
Relevance to US 7,566,729 |
| Compound and early therapeutic use |
Pirfenidone and pulmonary-fibrosis treatment claims |
Broader historical protection |
| Dose-regimen patents |
Titration, maintenance dosing, and treatment protocols |
Directly adjacent |
| Adverse-event management |
Rechallenge after liver-function abnormalities |
Core subject of US 7,566,729 |
| Formulation and dosage form |
Tablets, capsules, strength combinations, or pharmaceutical compositions |
Potentially relevant to product launch |
| Method-of-use patents |
Treatment of IPF or defined patient subgroups |
May affect skinny-label design |
| Manufacturing patents |
Synthesis, purification, or process controls |
More relevant to API suppliers than ANDA applicants |
US Patent 6,562,861 is an earlier InterMune-associated pirfenidone patent commonly identified with pirfenidone and pulmonary-fibrosis treatment rights. Its term and enforceability are separate from US 7,566,729 and should not be treated as extending the later liver-titration patent. [3]
The critical legal distinction is that expiration of US 7,566,729 does not establish freedom to operate against every pirfenidone patent. A launch review must separate:
- the active ingredient;
- the approved 267 mg and 801 mg dosage forms;
- the 2,403 mg/day regimen;
- liver-management instructions;
- manufacturing processes;
- any later-filed patents with valid patent-term adjustments.
What was the Orange Book status of US 7,566,729?
Esbriet was approved under NDA 022535 on October 15, 2014, for the treatment of IPF. [2] FDA Orange Book listings associated with an NDA can include patents directed to the drug substance, formulation, method of use, or approved dosing regimen. [4]
US 7,566,729 was relevant to the Orange Book patent landscape because its claims track the labeled management of pirfenidone-related liver abnormalities. Its claim scope was narrower than the approved IPF indication. The listing therefore created a potential Hatch-Waxman challenge point for an ANDA applicant seeking approval before patent expiration.
The patent’s February 2025 term endpoint materially changes its present commercial status. After expiration, the patent cannot block a product merely because the product contains pirfenidone or is approved for IPF. The residual risk would be limited to other unexpired patents and to conduct occurring before expiration.
When did pirfenidone lose regulatory exclusivity?
Pirfenidone’s principal regulatory exclusivities expired before the patent term of US 7,566,729.
| Protection |
Approximate period |
Commercial effect |
| New chemical entity exclusivity |
Five years from October 15, 2014 |
Prevented ANDA filing during the initial period |
| Orphan-drug exclusivity |
Seven years from approval |
Restricted approval of the same drug for IPF through approximately October 2021 |
| US 7,566,729 patent |
Through February 2025 based on ordinary term |
Created a separate patent-based barrier |
FDA approval of an ANDA can occur after regulatory exclusivity expires but before patent expiration if the applicant resolves listed patents through certification, litigation, settlement, or an authorized launch date. [5]
Which companies challenged or could challenge the patent?
Publicly disclosed pirfenidone patent disputes have involved the brand owner and multiple generic applicants. The relevant applicant universe has included large generic manufacturers and international suppliers seeking approval of pirfenidone tablets or capsules.
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. For this patent, likely challenge positions include:
- the claims are obvious in view of known pirfenidone dose-reduction and rechallenge practices;
- the patent lacks adequate written description for the claimed dose sequence or Grade 2 definition;
- the proposed generic label does not induce performance of the claimed method;
- the generic product is not responsible for a physician’s patient-specific decision after a liver abnormality;
- the claims are not infringed because the proposed label omits the patented rechallenge instructions.
The strongest infringement case would arise from a label that expressly instructs clinicians to stop pirfenidone after a Grade 2 abnormality, restart at 801 mg/day or 1,602 mg/day, and escalate to 2,403 mg/day. A label that provides only general warnings and leaves liver-event management to physician judgment presents a narrower inducement theory.
How strong is the patent estate for generic entry?
US 7,566,729 was commercially meaningful before expiration but structurally narrow.
| Strength factor |
Assessment |
| Clinical-label overlap |
High |
| Breadth of disease coverage |
Low; limited to IPF |
| Breadth of patient population |
Low; requires prior Grade 2 liver abnormality |
| Dose specificity |
High |
| Monitoring limitations |
Adds potential proof but also narrows scope |
| Product-by-process protection |
None apparent from the supplied claims |
| Generic label risk |
Moderate before expiration, low after expiration |
| Current blocking value |
None from this patent after term expiration |
The patent was stronger as a method-of-use enforcement tool than as a compound or product barrier. Its practical value depended on whether the brand label, generic label, or physician instructions caused performance of the complete sequence.
What generic launch scenarios existed?
Before February 2025, generic applicants had four principal routes:
- Paragraph IV litigation. The applicant challenged validity, enforceability, or infringement and sought approval after a favorable resolution.
- Label carve-out. The applicant removed or narrowed instructions corresponding to the patented liver-rechallenge method, where FDA labeling rules permitted the carve-out.
- Settlement with authorized entry. The applicant accepted a negotiated launch date or other commercial restrictions.
- Post-expiration launch. The applicant waited for the patent term to end, eliminating the direct barrier from US 7,566,729.
After expiration, the principal patent risk shifts to any unexpired formulation, dosage-form, manufacturing, or method-of-use patents listed for NDA 022535 or asserted independently.
What licensing deals affect pirfenidone rights?
InterMune commercialized pirfenidone in the United States and Europe before Roche acquired InterMune in 2014 for approximately $8.3 billion. [6] Roche became the principal commercial successor for Esbriet in those markets.
The corporate transaction transferred InterMune’s commercial and intellectual-property position but did not expand the scope of US 7,566,729. Any separate upstream license, regional right, or manufacturing agreement must be analyzed independently from the patent’s claim scope.
Key Takeaways
- US 7,566,729 covers a specific pirfenidone rechallenge protocol after a Grade 2 liver-function abnormality in an IPF patient.
- Claim 1 requires prior pirfenidone exposure, the specified liver event, reduced dosing, and later escalation to 2,400 or 2,403 mg/day.
- Claims 2 through 5 protect increasingly detailed interruption and dose-escalation sequences.
- Claims 6 through 9 add food administration, liver biomarkers, and monitoring requirements.
- The claims overlap materially with the FDA-approved Esbriet titration and liver-monitoring instructions.
- The patent does not cover pirfenidone as a compound, all IPF treatment, or ordinary initiation of the 801 mg three-times-daily regimen.
- The patent’s ordinary term ended in February 2025, removing it as a current standalone barrier to generic pirfenidone entry.
- Generic launch risk now depends primarily on other unexpired patents, product-specific claims, manufacturing rights, and any pre-expiration litigation or settlement obligations.
FAQs
Does US Patent 7,566,729 cover the 801 mg pirfenidone tablet?
No. The patent does not claim the tablet as a product. It claims a treatment method in which a patient with IPF and a prior Grade 2 liver abnormality is escalated to 2,400 or 2,403 mg/day.
Can a generic company omit the liver-titration instructions from its pirfenidone label?
Potentially. A generic applicant may seek a labeling carve-out where FDA rules permit removal of patented method-of-use information. The success of that strategy depends on the exact Orange Book use code, FDA labeling requirements, and whether the remaining label still encourages the claimed method.
Is the 2,403 mg/day dose different from the approved Esbriet dose?
No. It is the arithmetic total of 801 mg administered three times daily. The 2,400 mg/day alternative reflects an approximately equivalent daily dose.
Does patent expiration eliminate all pirfenidone generic-entry risk?
No. Expiration of US 7,566,729 removes only this patent as a barrier. Other patents covering formulations, dosage forms, manufacturing processes, or separate methods of use may remain relevant.
What evidence would be important in litigation over this patent?
The key evidence would include laboratory values, the clinical grading standard used for the liver abnormality, the physician’s knowledge of the event, the actual dose sequence, prescription instructions, the generic product label, and records showing whether treatment reached 2,400 or 2,403 mg/day.
References
- United States Patent and Trademark Office. (2009). U.S. Patent No. 7,566,729, Methods for treating pulmonary fibrosis.
- U.S. Food and Drug Administration. (2023). Esbriet (pirfenidone) prescribing information, NDA 022535.
- United States Patent and Trademark Office. (2003). U.S. Patent No. 6,562,861, Pirfenidone for the treatment of pulmonary fibrosis.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Amendments.
- F. Hoffmann-La Roche Ltd. (2014). Roche to acquire InterMune for approximately $8.3 billion. Company announcement.
